EUVIMEDEUVIMED entdecken
Crossref

Impact of calcitriol and PGD2-G-loaded lipid nanocapsules on oligodendrocyte progenitor cell differentiation and remyelination

Ariane Mwema iD, Viridiane Gratpain, Bernard Ucakar, Kevin Vanvarenberg, Océane Perdaens, Vincent van Pesch, Giulio G Muccioli, Anne des Rieux

Drug Delivery and Translational Research · 2024-11 · 14 (11) · 3128-3146

DOI: 10.1007/s13346-024-01535-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Delivery and Translational Research, online erschienen am 16.02.2024. Verfasst von Ariane Mwema und 7 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Drug Delivery and Biomaterials, Louvain Drug Research Institute, Université catholique de Louvain, UCLouvain, Avenue E. Mounier 73, 1200, Br…. Hauptthemen laut MEDLINE: Calcitriol, Cell Differentiation, Nanocapsules, Remyelination. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 110 Literaturangaben. Gefördert von: Fonds pour la Formation à la Recherche dans l'Industrie et dans l'Agriculture, Université Catholique de Louvain, Communauté française de Belgique.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple sclerosis (MS) is a demyelinating and inflammatory disease of the central nervous system (CNS) in need of a curative treatment. MS research has recently focused on the development of pro-remyelinating treatments and neuroprotective therapies. Here, we aimed at favoring remyelination and reducing neuro-inflammation in a cuprizone mouse model of brain demyelination using nanomedicines. We have selected lipid nanocapsules (LNC) coated with the cell-penetrating peptide transactivator of translation (TAT), loaded with either a pro-remyelinating compound, calcitriol (Cal-LNC TAT), or an anti-inflammatory bioactive lipid, prostaglandin D2-glycerol ester (PGD2-G) (PGD2-G-LNC TAT). Following the characterization of these formulations, we showed that Cal-LNC TAT in combination with PGD2-G-LNC TAT increased the mRNA expression of oligodendrocyte differentiation markers both in the CG-4 cell line and in primary mixed glial cell (MGC) cultures. However, while the combination of Cal-LNC TAT and PGD2-G-LNC TAT showed promising results in vitro, no significant impact, in terms of remyelination, astrogliosis, and microgliosis, was observed in vivo in the corpus callosum of cuprizone-treated mice following intranasal administration. Thus, although calcitriol's beneficial effects have been abundantly described in the literature in the context of MS, here, we show that the different doses of calcitriol tested had a negative impact on the mice well-being and showed no beneficial effect in the cuprizone model in terms of remyelination and neuro-inflammation, alone and when combined with PGD2-G-LNC TAT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CalcitriolCell DifferentiationNanocapsulesRemyelinationOligodendrocyte Precursor CellsCuprizoneAnimalsMiceMice, Inbred C57BLLipidsProstaglandin D2Demyelinating DiseasesDisease Models, AnimalCell LineMaleCells, Cultured

Stichwörter der Autor:innen

DemyelinationIntranasalNanoparticlesNeuro-inflammationNose-to-brain

Substanzen

CalcitriolNanocapsulesCuprizoneLipidsProstaglandin D2

Autor:innen und Institutionen

  • Advanced Drug Delivery and Biomaterials, Louvain Drug Research Institute, Université catholique de Louvain, UCLouvain, Avenue E. Mounier 73, 1200, Brussels, Belgium.
  • Bioanalysis and Pharmacology of Bioactive Lipids, Louvain Drug Research Institute, Université catholique de Louvain, UCLouvain, Avenue E. Mounier 73, 1200, Brussels, Belgium.
  • Cellular and Molecular Division, Institute of Neuroscience, Université catholique de Louvain, UCLouvain, Avenue E. Mounier 53, 1200, Brussels, Belgium.
  • Bioanalysis and Pharmacology of Bioactive Lipids, Louvain Drug Research Institute, Université catholique de Louvain, UCLouvain, Avenue E. Mounier 73, 1200, Brussels, Belgium. giulio.muccioli@uclouvain.be.
  • Advanced Drug Delivery and Biomaterials, Louvain Drug Research Institute, Université catholique de Louvain, UCLouvain, Avenue E. Mounier 73, 1200, Brussels, Belgium. anne.desrieux@uclouvain.be.

ORCID-Profile: Ariane Mwema

Förderung

  • Fonds pour la Formation à la Recherche dans l'Industrie et dans l'Agriculture
  • Université Catholique de Louvain
  • Communauté française de Belgique
  • Fonds pour la Formation à la Recherche dans l’Industrie et dans l’Agriculture

Zitieren

APA

Mwema, A., Gratpain, V., Ucakar, B., Vanvarenberg, K., Perdaens, O., van Pesch, V., Muccioli, G. G., & des Rieux, A. (2024). Impact of calcitriol and PGD2-G-loaded lipid nanocapsules on oligodendrocyte progenitor cell differentiation and remyelination. Drug Delivery and Translational Research, 14(11), 3128-3146. https://doi.org/10.1007/s13346-024-01535-8

Vancouver

Mwema A, Gratpain V, Ucakar B, Vanvarenberg K, Perdaens O, van Pesch V, et al. Impact of calcitriol and PGD2-G-loaded lipid nanocapsules on oligodendrocyte progenitor cell differentiation and remyelination. Drug Delivery and Translational Research. 2024;14(11):3128-3146. doi:10.1007/s13346-024-01535-8

BibTeX
@article{Mwema2024,
  author = {Mwema, Ariane and Gratpain, Viridiane and Ucakar, Bernard and Vanvarenberg, Kevin and Perdaens, Océane and van Pesch, Vincent and Muccioli, Giulio G and des Rieux, Anne},
  title = {Impact of calcitriol and PGD2-G-loaded lipid nanocapsules on oligodendrocyte progenitor cell differentiation and remyelination},
  journal = {Drug Delivery and Translational Research},
  year = {2024},
  volume = {14},
  number = {11},
  pages = {3128--3146},
  doi = {10.1007/s13346-024-01535-8}
}
Kostenlos starten →